BofA raised the firm’s price target on BrightSpring Health (BTSG) to $21 from $19 and keeps a Buy rating on the shares after having hosted a session with BrightSpring CEO Jon Rousseau. The company expects double-digit growth in 2025, largely driven by the outsized growth within the Specialty/Oncology pharmacy segment, notes the firm, which applies a higher multiple given increased confidence in estimates following the firm’s Home Care Conference event.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $21 from $17 at Wells Fargo
- BrightSpring Health price target raised to $20 from $13 at Deutsche Bank
- BrightSpring Health price target raised to $20 from $17 at Mizuho
- BrightSpring Health Services Reports Strong Q3 Growth
- BrightSpring Health reports Q3 adjusted EPS 11c, consensus 17c